Angiocrine Bioscience   Report issue

For profit Phase 1 Phase 3
Founded: New York NY United States (2012)

Organization Overview

First Clinical Trial
2018
NCT03483324
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Angiocrine Bioscience | Angiocrine Bioscience, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

ab-205 (2 trials)

Drugs in Phase 1 Trials (3)

allogeneic cord blood (1 trial)

autologous cd34+ cells (1 trial)

e-cel uvec (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fistula (Phase 1)

Leukemia (Phase 1)

Lymphoma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Rectal Fistula (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4